Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 885

1.

Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.

Helanterä I, Lautenschlager I, Koskinen P.

Nephrol Dial Transplant. 2009 Jan;24(1):316-20. doi: 10.1093/ndt/gfn558. Epub 2008 Oct 8.

PMID:
18842670
[PubMed - indexed for MEDLINE]
Free Article
2.

Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis.

Helanterä I, Kyllönen L, Lautenschlager I, Salmela K, Koskinen P.

Am J Transplant. 2010 Sep;10(9):2026-32. doi: 10.1111/j.1600-6143.2010.03225.x.

PMID:
20883536
[PubMed - indexed for MEDLINE]
Free Article
3.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?

Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.

Transplant Proc. 2005 Sep;37(7):3182-6.

PMID:
16213344
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.

Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK.

Pharmacotherapy. 2004 Oct;24(10):1323-30.

PMID:
15628830
[PubMed - indexed for MEDLINE]
5.

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.

Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group.

Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3.

PMID:
22094954
[PubMed - indexed for MEDLINE]
6.

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.

Transplantation. 1998 Dec 27;66(12):1682-8.

PMID:
9884259
[PubMed - indexed for MEDLINE]
7.

The risk of cytomegalovirus recurrence after kidney transplantation.

Helanterä I, Lautenschlager I, Koskinen P.

Transpl Int. 2011 Dec;24(12):1170-8. doi: 10.1111/j.1432-2277.2011.01321.x. Epub 2011 Sep 8.

PMID:
21902725
[PubMed - indexed for MEDLINE]
8.

Delayed-onset primary cytomegalovirus disease after liver transplantation.

Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR.

Liver Transpl. 2007 Dec;13(12):1703-9.

PMID:
18044717
[PubMed - indexed for MEDLINE]
Free Article
9.

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.

Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC.

Am J Transplant. 2006 Sep;6(9):2134-43. Epub 2006 Jun 19.

PMID:
16780548
[PubMed - indexed for MEDLINE]
Free Article
10.

Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.

Keven K, Basu A, Tan HP, Thai N, Khan A, Marcos A, Starzl TE, Shapiro R.

Transplant Proc. 2004 Dec;36(10):3107-12.

PMID:
15686707
[PubMed - indexed for MEDLINE]
11.

Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.

Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS.

Transplantation. 2007 Feb 15;83(3):290-6.

PMID:
17297403
[PubMed - indexed for MEDLINE]
12.

A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.

Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, Jackson K, Nia S, Lien D.

Am J Transplant. 2005 Jun;5(6):1462-8.

PMID:
15888055
[PubMed - indexed for MEDLINE]
Free Article
13.

Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.

Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.

Transplant Proc. 2007 Sep;39(7):2228-30.

PMID:
17889146
[PubMed - indexed for MEDLINE]
14.

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.

Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA.

Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.

PMID:
19642123
[PubMed - indexed for MEDLINE]
Free Article
15.

Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.

Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR.

Clin Transplant. 2008 Mar-Apr;22(2):162-70. doi: 10.1111/j.1399-0012.2007.00761.x.

PMID:
18339135
[PubMed - indexed for MEDLINE]
16.

Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.

Perrottet N, Manuel O, Lamoth F, Venetz JP, Sahli R, Decosterd LA, Buclin T, Pascual M, Meylan P.

BMC Infect Dis. 2010 Jan 6;10:2. doi: 10.1186/1471-2334-10-2.

PMID:
20053269
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.

Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.

Transpl Infect Dis. 2012 Jun;14(3):248-58. doi: 10.1111/j.1399-3062.2012.00723.x. Epub 2012 Mar 5.

PMID:
22385394
[PubMed - indexed for MEDLINE]
18.

Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.

Lopau K, Greser A, Wanner C.

Clin Transplant. 2007 Jan-Feb;21(1):80-5.

PMID:
17302595
[PubMed - indexed for MEDLINE]
19.

Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.

Len O, Gavaldà J, Aguado JM, Borrell N, Cervera C, Cisneros JM, Cuervas-Mons V, Gurguí M, Martin-Dávila P, Montejo M, Muñoz P, Bou G, Carratalà J, Torre-Cisneros J, Pahissa A; RESITRA.

Clin Infect Dis. 2008 Jan 1;46(1):20-7. doi: 10.1086/523590.

PMID:
18171208
[PubMed - indexed for MEDLINE]
Free Article
20.

Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.

Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC.

Antivir Ther. 2005;10(1):119-23.

PMID:
15751769
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk